U. K. Scientists Fear Government Will Muzzle Research Reports

New Rules Seen As Serious Threats To Academic Freedom LONDON--Gerald Draper is a worried man. Head of the Childhood Cancer Research Group at Oxford University, he often speaks at meetings of parents who live near nuclear installations, helping them understand why the risk of radiation-induced leukemia in their children is small. It is a daunting task, because the question of whether leukemia rates rise around nuclear power plants is one of the most contentious scientific issues in Britain.

Written byRichard Smith
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

LONDON--Gerald Draper is a worried man. Head of the Childhood Cancer Research Group at Oxford University, he often speaks at meetings of parents who live near nuclear installations, helping them understand why the risk of radiation-induced leukemia in their children is small.

It is a daunting task, because the question of whether leukemia rates rise around nuclear power plants is one of the most contentious scientific issues in Britain. But now, the British government has made Draper’s job even more difficult. It is trying to make him sign a contract that could prevent him from publishing his work. If his research showed even small clusters of leukemia, would the government muzzle him, Draper wonders? And if so, what parent would ever believe that he is telling the truth about nuclear power? The new research contracts, say Draper and scores of other scientists across Britain, represent an ominous and serious threat ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies